- Home
- APTV vs GMAB Comparison
APTV vs GMAB Comparison
Compare APTV & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APTV
- GMAB
- Stock Information
- Founded
- APTV 2011
- GMAB 1999
- Country
- APTV Switzerland
- GMAB Denmark
- Employees
- APTV N/A
- GMAB N/A
- Industry
- APTV Auto Parts:O.E.M.
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- APTV Consumer Discretionary
- GMAB Health Care
- Exchange
- APTV Nasdaq
- GMAB Nasdaq
- Market Cap
- APTV 14.1B
- GMAB 15.0B
- IPO Year
- APTV 1999
- GMAB N/A
- Fundamental
- Price
- APTV $61.80
- GMAB $21.80
- Analyst Decision
- APTV Buy
- GMAB Buy
- Analyst Count
- APTV 17
- GMAB 8
- Target Price
- APTV $84.00
- GMAB $43.00
- AVG Volume (30 Days)
- APTV 3.5M
- GMAB 1.1M
- Earning Date
- APTV 02-06-2025
- GMAB 02-12-2025
- Dividend Yield
- APTV N/A
- GMAB N/A
- EPS Growth
- APTV 11.88
- GMAB 14.35
- EPS
- APTV 9.04
- GMAB 10.80
- Revenue
- APTV $19,725,000,000.00
- GMAB $2,967,926,227.00
- Revenue This Year
- APTV $0.20
- GMAB $32.03
- Revenue Next Year
- APTV $2.69
- GMAB $16.97
- P/E Ratio
- APTV $6.83
- GMAB $19.02
- Revenue Growth
- APTV N/A
- GMAB 17.75
- 52 Week Low
- APTV $51.47
- GMAB $19.85
- 52 Week High
- APTV $88.89
- GMAB $31.88
- Technical
- Relative Strength Index (RSI)
- APTV 60.43
- GMAB 54.72
- Support Level
- APTV $60.26
- GMAB $19.89
- Resistance Level
- APTV $62.09
- GMAB $21.26
- Average True Range (ATR)
- APTV 1.37
- GMAB 0.42
- MACD
- APTV 0.06
- GMAB 0.02
- Stochastic Oscillator
- APTV 69.78
- GMAB 80.08
About APTV Aptiv PLC
Aptiv Holdings Ltd, formerly Aptiv PLC signal and power solutions segment supplies components and systems that make up a vehicle's electrical system, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, driver-assist technologies, and displays, as well as the development of software for these systems.
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.